Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Transposagen Biopharmaceuticals announces new TGEM Rat Model product line

Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today that it has added 170 genetically modified rats and related biomaterials to its database of laboratory rats with a genetic modification that can mimic a human disease. These animals are used by academic, pharmaceutical, and biotech scientists for drug discovery and development research and will be sold under Transposagen's new TGEM(TM) Rat Models brand.

23 Apr 2010

TUM scientists collaborate with Fujitsu Laboratories of Japan to commercialize biosensor chip

In the battle against cancer and other diseases, precise analysis of specific proteins can point the way toward targeted treatments. Scientists at theTechnische Universitaet Muenchen, together with Fujitsu Laboratories of Japan, have developed a novel biosensor chip that not only recognizes proteins that are characteristic for specific diseases, but also can show if these proteins are changed through the influence of disease or drugs.

23 Apr 2010

BUSM professor receives Individual Biomedical Research Award

Richard Goldstein, PhD, a professor of pediatrics, division of pediatric infectious diseases, at Boston University School of Medicine, has been awarded an Individual Biomedical Research Award by The Hartwell Foundation and will receive $300,000 over three years as a Hartwell Investigator for his project titled, "A Vaccine Against Streptococcus Pneumoniae Based on Bacterial Surface Proteins Phylogenically Certified as Highly Conserved."

23 Apr 2010

AB SCIEX to collaborate in disease studies with Samuel Lunenfeld Research Institute of Mount Sinai Hospital

AB SCIEX, a global leader in life science analytical technologies, today announced that it is collaborating with the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, one of the world's leading centers for biomedical research, to improve disease studies. The project is focused on better understanding cancer, diabetes and heart disease by advancing the study of proteins through the use of an emerging mass spectrometry platform currently under development by AB SCIEX.

22 Apr 2010

Human lymphocytes produce hepcidin that regulate iron levels in the body: Study

For some years now a small group of scientists have been pioneering a revolutionary idea - that the vertebrate immune system could have a role in the regulation of iron in the body. And now, a work soon to be published in the journal Immunology, shows that human lymphocytes (white blood cells) actually produce hepcidin, the most important protein in the regulation of iron levels in the body.

22 Apr 2010

IL-10 Gene Therapy helps repair damaged lungs found unfit for transplant

Promising research brings hope for the almost two thousand lung transplant candidates who currently make up The United Network for Organ Sharing's (UNOS) wait list. A new technique that uses gene therapy to help repair damaged lungs previously found unfit for transplant shows promise for addressing the critical shortage of healthy donor organs.

22 Apr 2010

Removable methyl groups on specific genes of autistic individuals that led to gene silencing identified

A new study by researchers at The George Washington University School of Medicine and Health Sciences' Department of Biochemistry and Molecular Biology raises hope that autism may be more easily diagnosed and that its effects may be more reversible than previously thought.

22 Apr 2010

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).

22 Apr 2010

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported results from two studies on the development of ribonuclease-based immunotoxins at the American Association for Cancer Research conference.

22 Apr 2010

Resonant activation can be a strategy against bacterial persistence: Virginia Tech biologist

A Virginia Tech biologist proposes to use a physics strategy called resonant activation to nudge dormant bacteria cells into a stage where they will be sensitive to antibiotics.

22 Apr 2010

Positive results from preclinical EP-302 program presented at AACR 2010

Drug discovery and development company Esperance Pharmaceuticals today presented positive results from their preclinical EP-302 program that support the initiation of IND enabling studies. EP-302 is a targeted membrane-disrupting peptide designed to selectively kill cells that express nucleolin on their surface. Nucleolin is a protein that is over-expressed in a wide range of cancers and tumor endothelial cells.

22 Apr 2010

Death protein ubiquitin binds to and activates RIG-I: UT Southwestern researchers

UT Southwestern Medical Center researchers have determined how a protein that normally latches onto molecules inside cells and marks them for destruction also gives life to the body's immune response against viruses.

22 Apr 2010

Research findings may help personalize use of statins, scientists say

Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered why statins -- popular drugs that lower cholesterol and appear to protect against colorectal cancer development -- work for some people, but not for all.

22 Apr 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.

22 Apr 2010

Genmab introduces new pre-clinical antibody program and novel bispecific antibody technology

Genmab A/S will announce today at its Annual General Meeting a new pre-clinical antibody program, HuMax-cMet,as well as a novel next generation bispecific antibody technology.

22 Apr 2010

SpectraCell Laboratories introduces apolipoprotein E genotyping

Effective immediately, SpectraCell Laboratories now offers apolipoprotein E genotyping. This test determines a person's genetic risk for heart disease associated with the commonly studied gene called apoE, which is involved in the metabolism of cholesterol and triglycerides (fats in the blood).

22 Apr 2010

New method to analyze molecular activity of cancer drugs for solid tumors using skin biopsies

A research team today reported clinical results of a new method for analyzing the molecular activity of cancer drugs for solid tumors using skin biopsies. The approach, enabled by Cambridge Research & Instrumentation, Inc.'s imaging and analysis systems, was presented in a poster session at the American Association of Cancer Research's Annual Meeting in Washington D.C.

21 Apr 2010

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that preclinical data was presented on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

21 Apr 2010

MicroRNAs control levels of Myc protein in Drosophila: Researchers

In all cancers, whether in kidney, breast, lung, colon, skin or any other tissue, cells show high Myc protein levels. Excess Myc causes cells to multiply in an exaggerated manner, giving rise to the development of tumours. One of the most pressing questions about Myc is how healthy cells keep the expression of this protein in check.

21 Apr 2010

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.

21 Apr 2010

Protein News and Research

Further Reading

Transposagen Biopharmaceuticals announces new TGEM Rat Model product line

TUM scientists collaborate with Fujitsu Laboratories of Japan to commercialize biosensor chip

BUSM professor receives Individual Biomedical Research Award

AB SCIEX to collaborate in disease studies with Samuel Lunenfeld Research Institute of Mount Sinai Hospital

Human lymphocytes produce hepcidin that regulate iron levels in the body: Study

IL-10 Gene Therapy helps repair damaged lungs found unfit for transplant

Removable methyl groups on specific genes of autistic individuals that led to gene silencing identified

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

Resonant activation can be a strategy against bacterial persistence: Virginia Tech biologist

Positive results from preclinical EP-302 program presented at AACR 2010

Death protein ubiquitin binds to and activates RIG-I: UT Southwestern researchers

Research findings may help personalize use of statins, scientists say

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

Genmab introduces new pre-clinical antibody program and novel bispecific antibody technology

SpectraCell Laboratories introduces apolipoprotein E genotyping

New method to analyze molecular activity of cancer drugs for solid tumors using skin biopsies

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

MicroRNAs control levels of Myc protein in Drosophila: Researchers

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News